The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 6 for:    mazindol

Mazindol for Cocaine Abuse - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000277
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 18, 2020
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Mazindol Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: Mazindol for Cocaine Abuse
Study Start Date : September 1994
Actual Primary Completion Date : August 1999
Actual Study Completion Date : August 1999

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Side effects
  2. Drug use
  3. Retention


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000277


Locations
Layout table for location information
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Investigators
Layout table for investigator information
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
Publications:
Substance Abuse, 18(3):125-131, 1997.

Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000277    
Other Study ID Numbers: NIDA-09250-2
P50DA009250 ( U.S. NIH Grant/Contract )
P50-09250-2
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: June 18, 2020
Last Verified: June 2020
Keywords provided by Yale University:
Cocaine-Related Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Mazindol
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Central Nervous System Stimulants
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Dopamine Uptake Inhibitors
Dopamine Agents